vs
Side-by-side financial comparison of AMDOCS LTD (DOX) and Edwards Lifesciences (EW). Click either name above to swap in a different company.
Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.3B, roughly 1.3× AMDOCS LTD). Edwards Lifesciences runs the higher net margin — 23.1% vs 11.2%, a 11.9% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 1.1%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs 4.5%).
Amdocs Limited is a multinational telecommunications technology company headquartered in Chesterfield, Missouri. The company specializes in software and services for communications, media and financial services providers and digital enterprises. Amdocs was founded in 1982 and is publicly traded on the Nasdaq stock exchange.
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
DOX vs EW — Head-to-Head
Income Statement — Q3 FY2024 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.6B |
| Net Profit | $140.3M | $380.7M |
| Gross Margin | — | 78.0% |
| Operating Margin | 14.1% | 1.8% |
| Net Margin | 11.2% | 23.1% |
| Revenue YoY | 1.1% | 16.7% |
| Net Profit YoY | -12.0% | 6.8% |
| EPS (diluted) | $1.21 | $0.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | $1.3B | $1.4B |
| Q1 26 | — | $380.7M | ||
| Q4 25 | — | $91.2M | ||
| Q3 25 | — | $291.1M | ||
| Q2 25 | — | $333.2M | ||
| Q1 25 | — | $358.0M | ||
| Q4 24 | — | $385.6M | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | $140.3M | $366.3M |
| Q1 26 | — | 78.0% | ||
| Q4 25 | — | 78.1% | ||
| Q3 25 | — | 77.8% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 79.9% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | 19.8% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 27.9% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 25.9% | ||
| Q2 24 | 14.1% | 26.8% |
| Q1 26 | — | 23.1% | ||
| Q4 25 | — | 5.8% | ||
| Q3 25 | — | 18.7% | ||
| Q2 25 | — | 21.7% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | — | 226.7% | ||
| Q2 24 | 11.2% | 26.7% |
| Q1 26 | — | $0.66 | ||
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.50 | ||
| Q2 25 | — | $0.56 | ||
| Q1 25 | — | $0.61 | ||
| Q4 24 | — | $0.65 | ||
| Q3 24 | — | $5.13 | ||
| Q2 24 | $1.21 | $0.61 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
